Comparison of Serum Albumin Separation by Ammonium Sulfate Precipitation and Cibacron Blue Affinity Chromatography

Year 2025, Volume: 4 Issue: 2, 63 - 75, 03.09.2025

Esmanur Çiğ , Tayfun Güldür

https://doi.org/10.71133/anatphar.1686487

Abstract

Serum albumin, which is synthesized in the liver and has many physiological functions, is one of the most abundant proteins in plasma. Albumin is a valuable biomarker of many diseases and has indications in many diseases. The increasing use of albumin in biotechnological applications, its important ligand-carrying properties and its wide range of applications in clinical and basic scientific studies require high purity serum albumin separation. Many methods such as ammonium sulfate precipitation, heat shock method, plasma fractionation with ethanol, chromatographic methods (column, affinity), acetone/trichloroacetic acid precipitation are used for albumin separation from serum. In this study, 2 methods based on ammonium sulfate precipitation and Cibacron Blue affinity chromatography were compared. The purity of the isolated proteins was monitored by SDS-PAGE and densitometrically analyzed. The selected methods were evaluated in terms of time, applicability, purity and cost. İt was concluded that ammonium sulfate precipitation provided a more successful separation in terms of albumin yield and purity compared to Cibacron Blue affinity chromatography.

Keywords

: Serum Albumin , Ammonium Sulfate , Cibacron Blue F3GA , Affinity Chromatography , Protein Fractionation

Ethical Statement

This study was approved by the Malatya Clinical Research Ethics Committee (2022/101).

Supporting Institution

This work was supported by the Inönü University, Scientific Research Projects Unit(TDK-2022-3130).

References

• [1] Quinlan GJ, Martin GS, Evans TW. Albumin: Biochemical properties and therapeutic potential. Hepatology, 2005;41:1211–9.
• [2] Farrugia A. Albumin Usage in Clinical Medicine: Tradition or Therapeutic? Transfus Med Rev, 2010;24(1):53–63.
• [3] Raoufinia R, Mota A, Nozari S, Aghebati Maleki L, Balkani S, Abdolalizadeh J. A methodological approach for purification and characterization of human serum albumin. J Immunoassay Immunochem, 2016;37(6):601–14.
• [4] Peters TJ. Metabolism: Albumin in the body. In: All About Albumin. Biochemistry, Genetics, and Medical Application, San Diego: Academic Press. 1996.
• [5] Evans TW. Review article: Albumin as a drug - Biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther Suppl, 2002;16(Suppl 5):6–11.
• [6] Mendez CM, McClain CJ, Marsano LS. Albumin therapy in clinical practice. Nutr Clin Pract, 2005;20(3):314–20.
• [7] Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature. Nutr J, 2010;9:69.
• [8] Denizli A. Plasma fractionation: conventional and chromatographic methods for albumin purification. Hacettepe Journal of Biology and Chemistry, 2011;39(394):315–41.
• [9] Koga M, Kasayama S. Clinical impact of glycated albumin as another glycemic control marker. Endocrine Journal, 2010;57(9):751–62.
• [10] Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes - Review and clinical implications. Clinical Chemistry and Laboratory Medicine, 2011;49(2):177–84.
• [11] Alexander MR, Alexander B, Mustion AL, Spector R, Wright CB. Therapeutic Use of Albumin: 2. Journal of the American Medical Association, 1982;247(6):793–7.
• [12] Erstad BL, Gales BJ, Rappaport WD. The Use of Albumin in Clinical Practice. Arch Intern Med, 1991;151(5):901–11.
• [13] Haynes GR, Navickis RJ, Wilkes MM. Albumin administration - What is the evidence of clinical benefit? A systematic review of randomized controlled trials. Eur J Anaesthesiol, 2003;20(10):771–93.
• [14] Rozga J, Piatek T, Małkowski P. Human albumin: Old, new, and emerging applications. Ann Transplant, 2013;18:205–17.
• [15] Bertucci C, Pistolozzi M, De Simone A. Circular dichroism in drug discovery and development: An abridged review. Anal Bioanal Chem, 2010;398(1):45–52.
• [16] Furukawa M, Tanaka R, Chuang VTG, Ishima Y, Taguchi K, Watanabe H, et al. Human serum albumin-thioredoxin fusion protein with long blood retention property is effective in suppressing lung injury. J Control Release, 2011;154(2):203–10.
• [17] Komatsu T, Qu X, Ihara H, Fujihara M, Azuma H, Ikeda H. Virus trap in human serum albumin nanotube. J Am Chem Soc, 2011;133(10):3770–3.
• [18] Chen Z, He Y, Shi B, Yang D. Human serum albumin from recombinant DNA technology: Challenges and strategies. Biochim Biophys Acta Gen Subj, 2013;1830(12):5515–25.
• [19] Kratz F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J Control Release, 2008;132(3):171–83.
• [20] Pilati D, Howard KA. Albumin-based drug designs for pharmacokinetic modulation. Expert Opin Drug Metab Toxicol, 2020;16(2):123–37.
• [21] Raoufinia R, Mota A, Keyhanvar N, Safari F, Shamekhi S, Abdolalizadeh J. Overview of Albumin and Its Purification Methods. Adv Pharm Bull, 2016 Dec;6(4):495-507.
• [22] Curling JM, Berglöf J, Lindquist L‐O, Eriksson S. A Chromatographic Procedure for the Purification of Human Plasma Albumin. Vox Sang, 1977;33(2):97–107.
• [23] Colantonio DA, Dunkinson C, Bovenkamp DE, Van Eyk JE. Effective removal of albumin from serum. Proteomics, 2005;5(15):3831–5.
• [24] Jovanović VB, Penezić-Romanjuk AZ, Pavićević ID, Aćimović JM, Mandić LM. Improving the reliability of human serum albumin-thiol group determination. Anal Biochem, 2013;439(1):17–22.
• [25] Pavićević ID, Jovanović VB, Takić MM, Aćimović JM, Penezić AZ, Mandić LM. Quantification of total content of nonesterified fatty acids bound to human serum albumin. J Pharm Biomed Anal, 2016;129:43–9.
• [26] Odunuga OO, Shazhko A. Ammonium sulfate precipitation combined with liquid chromatography is sufficient for purification of bovine serum albumin that is suitable for most routine laboratory applications. Biochem Compd, 2013;1(1).
• [27] Meral Ö, Pekcan M, Uysal H, Karagül H. Combined use of ion-exchange chromatography and ethanol fractionation in purification of canine and feline plasma albumin. Vet Hekim Der Derg, 2018;89(1):42–8.
• [28] Nelson, D. L., & Cox, M. C. (2004). Lehninger: Principles of Biochemistry (4th ed.). New York: W. H. Freeman.
• [29] Burgess RR. Protein precipitation techniques. Methods Enzymol, 2009;463:331-42.
• [30] Grodzki AC, Berenstein E. Antibody purification: ammonium sulfate fractionation or gel filtration. Methods Mol Biol, 2010;588:341–5.
• [31] Steel LF, Trotter MG, Nakajima PB, Mattu TS, Gonye G, Block T. Efficient and specific removal of albumin from human serum samples. Mol Cell Proteomics, 2003;2(4):262–70.
• [32] Travis J, Pannell R. Selective removal of albumin from plasma by affinity chromatography. Clin Chim Acta, 1973;49(1):49–55.
• [33] Gianazza E, Arnaud P. A general method for fractionation of plasma proteins. Dye-ligand affinity chromatography on immobilized Cibacron Blue F3-GA. Biochem J, 1982;201(1):129–38.
• [34] Hrkal Z. Chapter 6 Gel-Type Techniques. In: Deyl Z(ed). Journal of Chromatography Library, Vol. 18, Part A. Amsterdam: Elsevier; 1979. p. 113–31. [ISBN: 9780444417213.]
• [35] Rynö M, Anttinen-Klemetti T, Vaaranrinta R, Tornaeus J, Hesso A, Veidebaum T, et al. Scaled down method for the reproducible recovery to high purity of human serum albumin from low volume blood samples. Bioseparation, 2001;10(4–5):197– 201.
• [36] De Frutos M, Cifuentes A, Díez-Masa JC, Camafeita E, Méndez E. Multiple peaks in HPLC of proteins: Bovine serum albumin eluted in a reversed-phase system. J High Resolut Chromatogr, 1998;21(1):43–6.
• [37] Deutscher MP. Chapter 21 Affi-Gel Blue for Nucleic Acid Removal and Early Enrichment of Nucleotide Binding Proteins. In: Burgess RR, Deutscher MP(ed). Methods in Enzymology, Vol. 463. Amsterdam: Academic Press; 2009. p. 343–5. [ ISSN: 0076-6879.]
• [38] Baraka-Vidot J, Denemont I, Mcolo ZA, Bourdon E, Rondeau P. Ammonium Sulfate Precipitation but Not Delipidation is a Valuable Method for Human Albumin Preparation for Biological Studies. International Journal of Diabetes & Clinical Diagnosis, 2015;2(1):1–5.